# OrbiMed: portfolio, investments and team

> OrbiMed is a private equity based in United States. 447 investments on record, 55 in the last 12 months, latest Oct 2026.

Source: https://millionrounds.com/fund/orbimed (Millionrounds; every figure on the page links to its filing or article)

United States · [Investor](https://millionrounds.com/investors)

# OrbiMed

Last cheque observed Oct 2026; 447 cheques on record.

Email

Deploying now New fund $1.9B, Oct 2026 Private equity

Seed Series A Series B Healthcare Medtech Tech-enabled Health

Follow OrbiMed and see its new cheques in your feed. [Start following](https://millionrounds.com/login?join=1&why=follow&next=%2Ffund%2Forbimed)

Deploying now

**82%** of best year **55** **cheques in 12 months**, 447 on record

Since the last cheque **2** days **00** hrs **00** min **00** sec

Median round **$71M** Cheque size, as they say **$1.0M – $75M** Rounds led **9 of 447** Sole investor **32 rounds** Exits **23 from the portfolio** Mostly in **United States, 78%**

Pitch OrbiMed

## OrbiMed highlights

- 01 55 cheques in the last 12 months
- 02 Mostly Series B and Series A: 52% of its rounds
- 03 Sole investor in 32 rounds, median $30M
- 04 23 exits from the portfolio

## What they do

> We have been investing globally for over 25 years across the healthcare industry: from early-stage private companies to large multinational corporations. From their own website

- **Type:** Private equity (from a list, unverified)
- **Cheque size:** $1.0M – $75M as they say
- **Stages:** Seed Series A Series B Growth Pre-IPO
- **Sectors:** Healthcare Medtech Tech-enabled Health
- **Based in:** New York, United States
- **Cold pitches:** Not stated

## The record

Every round we can evidence, newest first **447 appearances**

- **2026** 42 rounds
- **Oct** **[Dren Bio](https://millionrounds.com/company/dren-bio)** US · Wowtale **$350M** With 13 others
- **Oct** **[Star Therapeutics](https://millionrounds.com/company/star-therapeutics)** US · Pulse 2.0 **$200M** *Led*
- **Sept** **[Altis Labs](https://millionrounds.com/company/altis-labs)** Series A · CA · BetaKit **$25M** *Led*
- **Sept** **[Intellia Therapeutics](https://millionrounds.com/company/intellia-therapeutics)** Debt · US **$400M** With 3 others
- **Sept** **[Helus Pharma](https://millionrounds.com/company/helus-pharma)** CA **$50M** With 3 others
- **Sept** **[Connexus Therapeutics](https://millionrounds.com/company/connexus-therapeutics)** Series A · HK **$5.0M** With 1 other
- **Jul** **[FORE Biotherapeutics](https://millionrounds.com/company/fore-biotherapeutics)** Series D · US · Ventureburn **$67M** With 15 others
- **Jul** **[Q32 Bio](https://millionrounds.com/company/q32-bio)** US **$200M** With 2 others
- **Jul** **[DarioHealth](https://millionrounds.com/company/dariohealth)** US **$24M** With 2 others
- **Jul** **[Erasca](https://millionrounds.com/company/erasca)** US **$633M** With 4 others
- **Jul** **TytoCare** Growth · US · Echo Health Ventures **$25M** With 11 others
- **Jun** **[TruNativ](https://millionrounds.com/company/trunativ)** Series B · IN · Inc42 **$30M** *Led*
- **Jun** **[Nuvation Bio](https://millionrounds.com/company/nuvation-bio)** Debt · US **$250M** With 4 others
- **Jun** **[Enliven Therapeutics](https://millionrounds.com/company/enliven-therapeutics)** US **$460M** With 3 others
- **Jun** **[Triveni Bio](https://millionrounds.com/company/triveni-bio)** Series C · US **$65M** With 4 others
- **Jun** **[Shattuck Labs](https://millionrounds.com/company/shattuck-labs)** US **$75M** With 4 others
- **May** **[Accro Bioscience](https://millionrounds.com/company/accro-bioscience)** Series C · CN · Ventureburn **$50M** *Led*
- **May** **[Whitehawk Therapeutics](https://millionrounds.com/company/whitehawk-therapeutics)** US **$88M** With 2 others
- **May** **[Avalo Therapeutics](https://millionrounds.com/company/avalo-therapeutics)** US **$431M** With 3 others
- **May** **[Apogee Therapeutics](https://millionrounds.com/company/apogee-therapeutics)** Debt · US **$1.3B** With 3 others
- **Apr** **[Adcendo](https://millionrounds.com/company/adcendo)** Series C · DK · Ventureburn **$75M** With 9 others
- **Apr** **[Sidewinder Therapeutics](https://millionrounds.com/company/sidewinder-therapeutics)** Series B · US · Ventureburn **$137M** With 8 others
- **Apr** **[SpectronRx](https://millionrounds.com/company/spectronrx)** US · Ventureburn **$85M** Sole investor
- **Apr** **[vVardis](https://millionrounds.com/company/vvardis)** Venture · CH **Undisclosed** With 1 other
- **Apr** **[ImageneBio](https://millionrounds.com/company/imagenebio)** US **$30M** With 4 others
- **Apr** **[Nucleus RadioPharma](https://millionrounds.com/company/nucleus-radiopharma)** Growth · US **$50M** With 2 others
- **Apr** **[Adela](https://millionrounds.com/company/adela)** US **$5.0M** With 2 others
- **Apr** **[Forte Biosciences](https://millionrounds.com/company/forte-biosciences)** US **$150M** With 2 others
- **Apr** **[Terremoto Biosciences](https://millionrounds.com/company/terremoto-biosciences)** Series C · US **$108M** With 3 others
- **Apr** **[Prelude Therapeutics](https://millionrounds.com/company/prelude-therapeutics)** US **$90M** With 2 others
- **Mar** **[Congruence Therapeutics](https://millionrounds.com/company/congruence-therapeutics)** CA · Lumira Ventures **$40M** *Led*
- **Mar** **[Stairway Medical](https://millionrounds.com/company/stairway-medical)** Venture **$73M** With 4 others
- **Mar** **[Apollomics](https://millionrounds.com/company/apollomics)** Debt · US **$2.0M** With 1 other
- **Mar** **[QL Biopharma](https://millionrounds.com/company/ql-biopharma)** Series C **$73M** With 3 others
- **Mar** **[Pinnacle Medicines](https://millionrounds.com/company/pinnacle-medicines)** Series B · US **$89M** With 3 others
- **Feb** **[Xilio Therapeutics](https://millionrounds.com/company/xilio-therapeutics)** US **$40M** With 3 others
- **Feb** **[QuantX Biosciences](https://millionrounds.com/company/quantx-biosciences)** Series B · US **$85M** With 3 others
- **Jan** **[Mendra](https://millionrounds.com/company/mendra)** Series A · US **$82M** With 4 others
- **Jan** **[Corvus Pharmaceuticals](https://millionrounds.com/company/corvus-pharmaceuticals)** US **$201M** With 4 others
- **Jan** **[Pee Safe](https://millionrounds.com/company/pee-safe)** Series C **$32M** With 2 others

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

## The team

Named by the firm itself, on a filing, its Form ADV or its company registration **24 named**

AM **Alexander Matthew Cooper** General Counsel i Form ADV

BK **Barbra Kocsis** Manager of the Administrator i Filing they signed

BL **Brendan Lake** Related person is managing member of the general partner i Filing they signed

BH **Brian H. Burkholder** Director i Filing they signed

BW **Brian Woldow** Manager of the Administrator i Filing they signed

CS **C. Scotland Stevens** Member of the Managing Member of the General Partner i Filing they signed

CL **Carl Lee Gordon** Member of the Managing Member of the General Partner i Filing they signed

CS **Charles Scotland Stevens** Member i Form ADV

CR **Colleen Rusch** Director of the General Partner i Filing they signed

DS **David Scotland Bonita** Member of the Managing Member of the General Partner i Filing they signed

DG **David G. Wang** Director of the GPLTD i Filing they signed

DM **Deann Morgan** Director of the General Partner i Filing they signed

DS **Devesh Saksena** Manager of the Administrator i Filing they signed

DW **Douglas W. Coon** Chief Compliance Officer i Form ADV

EL **Edward L. Truitt, Jr.** Executive Officer i Filing they signed

ED **Evan D. Sotiriou** Director i Filing they signed

GC **Geoffrey Che-Chang Hsu** Member of the Managing Member of the General Partner i Filing they signed

GB **Graham B.R. Collis** Director i Filing they signed

JC **James Costabile** Manager of the Managing Trustee i Filing they signed

JM **Jeff McGoey** Director of the General Partner i Filing they signed

JL **John Leale** Manager of the Administrator i Filing they signed

JT **Jonathan T. Silverstein** Member of the Managing Member of the General Partner i Filing they signed

KG **Keith Glenfield** Manager of the Managing Trustee i Filing they signed

LR **Leslie Ross** Manager of the Administrator i Filing they signed

We also hold **98** people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.

## What the register says

From the firm's own filings with the SEC, which it must file accurately by law

**$21B** assets it manages Oct 2026

**10+** funds on file numbered funds in its name

**Registered** investment adviser full reporting to the SEC

- **Legal name:** Orbimed Advisors LLC
- **SEC number:** CRD 118608

Funds on its Form ADV

**20** private funds, **$15B** in gross assets · filed Mar 2024

Fund meets the definition of **11** Hedge **6** Private equity **3**

- OrbiMed Private Investments IX, L.P. *Fund meets the definition of* 292 investors $1.9B
- OrbiMed ASIA Partners III, L.P. *Fund meets the definition of* 117 investors $1.8B
- OrbiMed Private Investments VIII, L.P. *Fund meets the definition of* 186 investors $1.7B
- OrbiMed Royalty & Credit Opportunities IV, L.P. *Private equity* 405 investors $1.5B
- OrbiMed Private Investments VII, L.P. *Fund meets the definition of* 145 investors $1.4B
- OrbiMed Private Investments VI, L.P. *Fund meets the definition of* 140 investors $1.0B
- OrbiMed Royalty & Credit Opportunities III, L.P. *Private equity* 113 investors $968M
- OrbiMed ASIA Partners IV, L.P. *Fund meets the definition of* 132 investors $933M
- OrbiMed Partners Master Fund Limited *Hedge* 195 investors $775M
- OrbiMed ASIA Partners V, L.P. *Fund meets the definition of* 95 investors $733M

And 10 more on the filing.

Who backs their funds

## 2 LPs on record in OrbiMed's funds

- **Committed:** $545M
- **Funds:** 8
- **Vintages:** 2009 to 2025

The institutions that put money into its funds, which the firm then invests in companies. Source: the pension's own report, latest Sept 2025.

- [**California State Teachers Retirement System** 7 funds *$405M*](https://millionrounds.com/fund/california-state-teachers-retirement-system) Fund Vintage Committed OrbiMed Royalty Credit Opps V 2025 $75M OrbiMed Private Investments IX 2022 $75M OrbiMed Royalty Credit Opps IV 2022 $75M OrbiMed Private Investments VIII 2020 $50M OrbiMed Royalty & Credit Opportunities III 2019 $50M OrbiMed Private Investments V 2013 $40M OrbiMed Private Investments IV 2010 $40M
- [**Oregon Public Employees Retirement Fund** 3 funds *$140M*](https://millionrounds.com/fund/oregon-public-employees) Fund Vintage Committed OrbiMed Private Investments VI 2015 $60M OrbiMed Private Investments V 2013 $40M OrbiMed Private Investments IV 2009 $40M

## What they claim to have backed

From their own portfolio page (on their website)

**21** of 60 we have independently watched raise

[world](https://millionrounds.com/company/acutus-medical)[world](https://millionrounds.com/company/aspen-neuroscience)[world](https://millionrounds.com/company/bioage-labs)[world](https://millionrounds.com/company/evox-therapeutics)[world](https://millionrounds.com/company/fore-biotherapeutics)[world](https://millionrounds.com/company/tela-bio)[world](https://millionrounds.com/company/pathai)[world](https://millionrounds.com/company/enyo-pharma)[world](https://millionrounds.com/company/disc-medicine)[world](https://millionrounds.com/company/cyrus-biotechnology)[world](https://millionrounds.com/company/nerre-therapeutics)[world](https://millionrounds.com/company/adicet-bio)[world](https://millionrounds.com/company/compass-therapeutics)[world](https://millionrounds.com/company/sidewinder-therapeutics)[world](https://millionrounds.com/company/inventisbio)[world](https://millionrounds.com/company/neuropace)[world](https://millionrounds.com/company/trunativ)[world](https://millionrounds.com/company/altis-labs)[world](https://millionrounds.com/company/aerin-medical)[world](https://millionrounds.com/company/alentis-therapeutics)[world](https://millionrounds.com/company/adcendo) world world world world world world world world world world world world world world world world world world world world world world world world world world world world world world world world world world world world world world world and 100 more

Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.

## Exits from the portfolio

Companies it backed that were later bought or listed **23 in all**

**[Cardioxyl Pharmaceuticals](https://millionrounds.com/company/cardioxyl-pharmaceuticals)** Bought by [Bristol-Myers Squibb](https://millionrounds.com/fund/bristol-myers-squibb) **$2.0B** Nov 2015

**[Receptos](https://millionrounds.com/company/receptos)** Bought by [Celgene](https://millionrounds.com/fund/celgene) **$7.3B** Jul 2015

**[CardiAQ Valve Technologies](https://millionrounds.com/company/cardiaq-valve-technologies)** Bought by [Edwards Lifesciences](https://millionrounds.com/fund/edwards-lifesciences) **$350M** Jul 2015

**[Auxilium Pharmaceuticals](https://millionrounds.com/company/auxilium-pharmaceuticals)** Bought by Endo Health Solutions **$2.6B** Oct 2014

**[Ambit Biosciences](https://millionrounds.com/company/ambit-biosciences)** Bought by [Daiichi Sankyo](https://millionrounds.com/fund/daiichi-sankyo) **$410M** Sept 2014

**[Civitas Therapeutics](https://millionrounds.com/company/civitas-therapeutics)** Bought by Acorda Therapeutics **$525M** Sept 2014

**[Seragon Pharmaceuticals](https://millionrounds.com/company/seragon-pharmaceuticals)** Bought by [Genentech](https://millionrounds.com/fund/genentech) **$725M** Jul 2014

**[Rempex Pharmaceuticals](https://millionrounds.com/company/rempex-pharmaceuticals)** Bought by The Medicines Company **$464M** Dec 2013

**[Aragon Pharmaceuticals](https://millionrounds.com/company/aragon-pharmaceuticals)** Bought by [Johnson & Johnson](https://millionrounds.com/fund/johnson-and-johnson) **$1.0B** Jun 2013

**[ACADIA Pharmaceuticals](https://millionrounds.com/company/acadia-pharmaceuticals)** Listed **$115M** May 2013

**[Vessix Vascular](https://millionrounds.com/company/vessix-vascular)** Bought by [Boston Scientific](https://millionrounds.com/fund/boston-scientific) **$300M** Nov 2012

**[EUSA Pharma](https://millionrounds.com/company/eusa-pharma)** Bought by [Jazz Pharmaceuticals](https://millionrounds.com/fund/jazz-pharmaceuticals) **$650M** Apr 2012

**[SuperDimension](https://millionrounds.com/company/superdimension)** Bought by [Covidien](https://millionrounds.com/fund/covidien) **$300M** Mar 2012

**[Enobia Pharma](https://millionrounds.com/company/enobia-pharma)** Bought by [Alexion Pharmaceuticals](https://millionrounds.com/fund/alexion-pharmaceuticals) **Undisclosed** Dec 2011

**[Innovative Spinal Technologies](https://millionrounds.com/company/innovative-spinal-technologies)** Bought by Theken Spine **$9.3M** Sept 2009

**[Arius Research](https://millionrounds.com/company/arius-research)** Bought by Roche **$143M** Jul 2008

**[SGX Pharmaceuticals](https://millionrounds.com/company/sgx-pharmaceuticals)** Bought by [Eli Lilly](https://millionrounds.com/fund/eli-lilly) **$66M** Jul 2008

**[CryoCor](https://millionrounds.com/company/cryocor)** Bought by [Boston Scientific](https://millionrounds.com/fund/boston-scientific) **Undisclosed** May 2008

**[EUSA Pharma](https://millionrounds.com/company/eusa-pharma)** Bought by EUSA Pharma **$23M** Mar 2008

**[Auxilium Pharmaceuticals](https://millionrounds.com/company/auxilium-pharmaceuticals)** Listed **Undisclosed** Dec 2007

The latest 20 here. An exit counts when it came after the firm's first round in the company. From historical deal records.

New fund on file

**$1.9B**

raised in Oct 2026

From its SEC filing, not a journalist: a firm that has just raised has money to deploy.

## The cheque

Seed Series A Series B

Median round joined **$71M** the round, not its cheque Alone, median **$30M**

Led 9 of 447 rounds **2%**

- **Said size:** $1.0M – $75M
- **Sole investor:** 32 rounds
- **Last cheque:** Oct 2026
- **Exits:** 23 from the portfolio

Rounds by stage said on their site

- Series B said *97*
- Series A said *72*
- Series C *71*
- Venture *53*
- Series D *33*
- Seed said *-*
- Growth said *-*

Cheques by month Led Joined

Nov 2023 Oct 2026

Often in the room with

- [RA Capital Management](https://millionrounds.com/fund/ra-capital-management) 52
- [Cormorant Asset Management](https://millionrounds.com/fund/cormorant-asset-management) 27
- [New Enterprise Associates](https://millionrounds.com/fund/new-enterprise-associates) 25
- [Perceptive Advisors](https://millionrounds.com/fund/perceptive-advisors) 23
- [5AM Ventures](https://millionrounds.com/fund/5am-ventures) 22
- [Foresite Capital](https://millionrounds.com/fund/forsite-capital) 22

**Pitching OrbiMed?** Put them on your fundraising board with this record on the card, and follow them to hear when they write a new cheque.

Add to your CRM *→*

## Who they invest alongside

The investors most often in the same rounds as OrbiMed. A count of rooms they were both in, not a relationship either has claimed.

[**RA Capital Management** Private equity **52** rounds together](https://millionrounds.com/fund/ra-capital-management)[**Cormorant Asset Management** Private equity **27** rounds together](https://millionrounds.com/fund/cormorant-asset-management)[**New Enterprise Associates** VC firm **25** rounds together](https://millionrounds.com/fund/new-enterprise-associates)[**Perceptive Advisors** Asset manager **23** rounds together](https://millionrounds.com/fund/perceptive-advisors)[**5AM Ventures** VC firm **22** rounds together](https://millionrounds.com/fund/5am-ventures)[**Foresite Capital** Private equity **22** rounds together](https://millionrounds.com/fund/forsite-capital)[**Janus Henderson Investors** Private equity **19** rounds together](https://millionrounds.com/fund/janus-henderson-investors)[**Novo Holdings** VC firm **18** rounds together](https://millionrounds.com/fund/novo-ventures)[**Wellington Management** VC firm **18** rounds together](https://millionrounds.com/fund/wellington-management)[**Fidelity** VC firm **17** rounds together](https://millionrounds.com/fund/fidelity)[**Polaris Partners** VC firm **16** rounds together](https://millionrounds.com/fund/polaris-partners)[**Qiming Venture Partners** VC firm **16** rounds together](https://millionrounds.com/fund/qiming-venture-partners)

## Recently backed

The latest companies OrbiMed put money into.

[**Dren Bio** $350M · Oct 2026](https://millionrounds.com/company/dren-bio)[**Star Therapeutics** $200M · Oct 2026](https://millionrounds.com/company/star-therapeutics)[**Altis Labs** $25M · Sept 2026](https://millionrounds.com/company/altis-labs)[**Intellia Therapeutics** $400M · Sept 2026](https://millionrounds.com/company/intellia-therapeutics)[**Helus Pharma** $50M · Sept 2026](https://millionrounds.com/company/helus-pharma)[**FORE Biotherapeutics** $67M · Jul 2026](https://millionrounds.com/company/fore-biotherapeutics)

## Quick answers about OrbiMed

### What does OrbiMed invest in?

OrbiMed invests most often at Series B and Series A (52% of the rounds on record), in sectors such as Healthcare, Medtech and Tech-enabled Health.

### How active is OrbiMed?

447 investments on record, 55 of them in the last 12 months, and it led 9. The most recent was in Oct 2026.

### What has OrbiMed invested in recently?

Its most recent investments on record: Dren Bio (Undisclosed round, Oct 2026), Star Therapeutics (Undisclosed round, Oct 2026) and Altis Labs (Series A, Sept 2026).

### How big are OrbiMed's cheques?

The median round it joins is $71M. It says it writes cheques of $1.0M to $75M.

### Does OrbiMed lead rounds?

Sometimes: it led 9 of its 447 investments on record (2%).

### Where does OrbiMed invest?

Most of the companies it backs are in the United States (78%) and Canada (8%).

### Is OrbiMed investing now?

Yes: it is actively investing, with 55 investments in the last 12 months.

### Who does OrbiMed invest alongside?

Most often RA Capital Management (52 rounds together), Cormorant Asset Management (27 rounds together) and New Enterprise Associates (25 rounds together).

## Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Find similar investorsOpen your CRM

Built from the rounds we watched, its filings and its own website, refreshed every night. [How we count](https://millionrounds.com/methodology) · [Report a correction](https://millionrounds.com/corrections?slug=orbimed) · [Is this your firm? Claim it](https://millionrounds.com/claim?org=orbimed)